Monitor for the MGX-001 IND filing expected in Q4 2026, which will be a key catalyst. The preclinical durability and safety data are supportive, but clinical proof-of-concept in humans remains the critical de-risking event.
Price Chart
Executive Summary
Metagenomi Therapeutics filed a September 2026 corporate presentation under Item 7.01, highlighting its lead hemophilia A program MGX-001 advancing toward an IND filing in Q4 2026, with supportive preclinical data showing durable FVIII expression and a favorable safety profile. The company reported $120.7 million in cash at Q2 2026, with runway through Q4 2027, and outlined a pipeline expansion into cardiometabolic diseases via a strategic partnership with Ionis.
Key Facts
- Lead program MGX-001 for hemophilia A is in IND-enabling stage with IND submission planned for Q4 2026
- Preclinical NHP data showed durable FVIII expression over ~19 months with stable activity levels
- Off-target evaluation tested 623 potential sites at up to 32x therapeutic dose in PHH; no off-target edits identified
- Cash position of $120.7 million at end of Q2 2026; runway expected through Q4 2027
- Strategic partnership with Ionis for 4 cardiometabolic targets (TTR, AGT, APOC3, undisclosed) with two co-development/co-commercialization options
- Pre-IND interaction with FDA completed December 2025 with collaborative, favorable outcome
Financial Impact
Cash runway through Q4 2027 based on $120.7M cash position; no revenue or earnings reported
Risk Factors
- MGX-001 is still preclinical; clinical trial risks include safety, efficacy, and patient enrollment
- Cash runway only through Q4 2027; may require additional financing before clinical data readout
- Competitive landscape includes approved gene therapies for hemophilia A and other in vivo gene editing programs
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-397037 |
| Document: mgx-ex99_1.htm | 0001193125-26-397037 |
| Document: 0001193125-26-397037-index-headers.html | 0001193125-26-397037 |
| Document: 0001193125-26-397037-index.html | 0001193125-26-397037 |
| Document: 0001193125-26-397037.txt | 0001193125-26-397037 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 21, 2026 4w ago | 8-K | $1.14 $0.8310 | ▼ −27.11% | ▼ −26.55% | $0.7674 (−32.68%) |
Aug 10, 2026 11w ago | 8-K | $1.21 $1.15 | ▲ +4.96% | ▲ +3.90% | $0.7674 (+36.58%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.7674 (−37.61%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.7674 (−37.61%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.7674 (−37.61%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.7674 (−37.61%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.7674 (−37.61%) |
May 11, 2026 24w ago | 8-K | $1.35 $1.23 | ▼ −8.89% | ▼ −7.16% | $0.7674 (−43.16%) |
May 11, 2026 24w ago | Press Release | $1.35 $1.23 | ▲ +8.89% | ▲ +7.16% | $0.7674 (+43.16%) |
Apr 27, 2026 26w ago | DEFA14A | $1.44 $1.36 | ▼ −5.56% | ▼ −11.02% | $0.7674 (−46.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers